{"changeSha256":"c9a87a104668fe2685a5cd2c26a0145e3c9552a31f9203058d2039f78f906a30","changedAt":"2026-11-14","changedFields":[{"after":"FDA-approved as Sandostatin and other octreotide products","before":"U.S. label record","field":"Status"},{"after":"A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.","before":"A somatostatin analogue. This profile cites a U.S. label record.","field":"Profile summary"},{"after":"The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.","before":"The cited DailyMed label identifies Octreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.","field":"Evidence note"},{"after":"Octreotide acetate, Sandostatin","before":"Octreotide acetate","field":"Related names"},{"after":"dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098, journal-pmid-2229278, journal-pmid-34953531","before":"dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda019667-1988-10-21-b49b130f234b]","before":"U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]","field":"Named organizations"},{"after":"name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b, fda-drugs-nda021008-1998-11-25-5b27b64436f4, fda-drugs-nda208232-2020-06-26-da026b3e2a4a, fda-drugs-nda213224-2024-09-27-08bf6f091098; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, fda-drugs-nda019667-1988-10-21-b49b130f234b; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2, journal-pmid-2229278, journal-pmid-34953531","before":"name: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; aliases: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; category: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; status: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; summary: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2; evidenceNote: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/octreotide/versions/3/","version":3},"id":"profile:octreotide:v3","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-status-changed","notice":"We added a plain-language reader guide with cited answers, re-checked the generic octreotide label, and added Drugs@FDA approval records and two randomized acromegaly trials from our human evidence review.","peptideSlugs":["octreotide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/octreotide/v2.json","sha256":"400efaae2d1cef96fbde97bf7ea5b832fa3b3defb22e34770980e00fd7596f27"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/octreotide/versions/2/","version":2},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"Octreotide acetate injection, solution · SPL version 2 · published 2026-02-02","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=387d7f8d-9762-4f6b-99e1-bdc50b8a1633&version=2","verifiedAt":"2026-07-22"},{"id":"fda-drugs-nda019667-1988-10-21-b49b130f234b","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA019667 · original submission status AP · 1988-10-21 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA019667%22&limit=1","verifiedAt":"2026-08-14"},{"id":"journal-pmid-2229278","name":"The Journal of Clinical Endocrinology & Metabolism","sourceClass":"A","title":"Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects (1990) · PMID 2229278","url":"https://doi.org/10.1210/jcem-71-5-1189","verifiedAt":"2026-11-14"},{"id":"journal-pmid-34953531","name":"The Lancet Diabetes & Endocrinology","sourceClass":"A","title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial (MPOWERED, 2022) · PMID 34953531","url":"https://doi.org/10.1016/S2213-8587(21)00296-5","verifiedAt":"2026-11-14"}],"subject":{"slug":"octreotide","type":"profile"}}
